89bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ETNB Nasdaq 8731 https://www.89bio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 89bio Inc

Why Shares of 89bio Soared This Week - Mar 24th, 2023 2:57 pm
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock - Mar 24th, 2023 11:00 am
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Mar 22nd, 2023 8:16 pm
Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up - Mar 22nd, 2023 8:09 pm
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks - Mar 22nd, 2023 11:00 am
12 Best Biotech Stocks To Buy Under $20 - Mar 21st, 2023 9:10 pm
Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High? - Mar 15th, 2023 1:55 pm
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update - Mar 10th, 2023 1:00 pm
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology - Mar 4th, 2023 6:30 pm
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology - Feb 21st, 2023 1:00 pm
89bio to Participate in the SVB Securities Global Biopharma Conference - Feb 8th, 2023 1:00 pm
Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag - Jan 24th, 2023 2:28 pm
With stock up 19%, Insiders of 89bio, Inc. (NASDAQ:ETNB) must be wishing they had bought more last year - Jan 22nd, 2023 2:21 pm
89bio Provides Business Update and Outlook for 2023 - Jan 4th, 2023 9:01 pm
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology - Dec 12th, 2022 11:30 pm
Analysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023 - Nov 25th, 2022 9:04 am
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 10th, 2022 9:05 pm
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022 - Nov 5th, 2022 5:00 pm
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference - Oct 13th, 2022 12:00 pm
10 Best Biotech Stocks Under $10 - Sep 26th, 2022 1:21 pm